Please ensure Javascript is enabled for purposes of website accessibility

Novavax Receives $4 Million in Funding to Develop a Vaccine for COVID-19

By Prosper Junior Bakiny - Mar 10, 2020 at 3:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Novavax's attempt to develop a vaccine for COVID-19 just got a helping hand.

Novavax (NVAX -5.01%), a clinical-stage biotechnology company, is currently perceived as one of the leaders in the race to develop a vaccine for COVID-19. The company recently announced it received a grant of $4 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to support its efforts to develop a vaccine for the potentially deadly disease, news that sent Novavax's shares soaring Tuesday

Novavax, which previously developed vaccines for other coronaviruses, is in the process of evaluating several "nanoparticle vaccine candidates" in animals before moving on to phase 1 clinical trials, which should start in late spring. The company is still in discussion with CEPI and could receive additional funding from the foundation soon.

Novavax also entered into an agreement with Emergent BioSolutions (EBS -3.48%) -- a Maryland-based biopharmaceutical company -- to advance the development of its potential vaccine for COVID-19. Under the terms of the agreement, Emergent will be tasked with manufacturing and producing Novavax's potential vaccine for COVID-19. 

A person wearing blue gloves filling a syringe with clear liquid from a glass vial.

Image Source: Getty Images.

Nearing pandemic levels

The COVID-19 epidemic isn't slowing down. In the U.S., the number of confirmed cases increased significantly over the weekend, and there are now more than 750 confirmed cases in more than 30 states. Worldwide, there are more than 110,000 cases across more than 100 countries, along with more than 4,000 deaths. 

According to the World Health Organization (WHO), COVID-19 is dangerously close to becoming a full-blown pandemic. This threat makes Novavax's efforts to develop a vaccine for the disease worth keeping a close eye on. Other biotech companies are working on developing vaccines or treatments for COVID-19 as well, and whichever one succeeds could well prevent a worldwide pandemic. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$57.25 (-5.01%) $-3.02
Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
EBS
$30.55 (-3.48%) $-1.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.